Published in Gastroenterology on February 13, 2011
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology (2014) 2.27
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology (2015) 1.56
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem (2012) 1.39
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget (2014) 1.22
MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal (2013) 1.16
Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One (2012) 1.10
Small regulatory RNAs controlled by genomic imprinting and their contribution to human disease. Epigenetics (2012) 1.10
A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One (2012) 1.03
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer (2014) 1.00
A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res (2014) 0.97
Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One (2014) 0.97
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer (2013) 0.96
Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol (2013) 0.95
Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett (2012) 0.95
The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer (2013) 0.94
Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med (2014) 0.92
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90
MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol (2013) 0.88
A functional genomics screen for microRNA regulators of NF-kappaB signaling. BMC Biol (2013) 0.86
Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology (2012) 0.86
MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol (2015) 0.86
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne) (2015) 0.85
Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Res Notes (2013) 0.85
Deregulation of epigenetic mechanisms by the hepatitis B virus X protein in hepatocarcinogenesis. Viruses (2013) 0.85
Watch the GAP: Emerging Roles for IQ Motif-Containing GTPase-Activating Proteins IQGAPs in Hepatocellular Carcinoma. Int J Hepatol (2012) 0.84
Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer (2015) 0.84
Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol (2013) 0.83
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One (2013) 0.83
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol (2012) 0.83
Genetic variants in microRNAs and breast cancer risk in African American and European American women. Breast Cancer Res Treat (2013) 0.82
miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer. Oncol Lett (2016) 0.81
MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma. World J Gastroenterol (2016) 0.81
A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. PLoS One (2014) 0.80
MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol (2014) 0.80
The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol (2013) 0.79
A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population. PLoS One (2014) 0.79
A Potential of microRNAs for High-Content Screening. J Nucleic Acids (2011) 0.79
MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression. Oncotarget (2016) 0.79
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine (2016) 0.78
Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol (2015) 0.78
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget (2015) 0.77
Involvement of miR-518c-5p to growth and metastasis in oral cancer. PLoS One (2014) 0.77
Activation of the two microRNA clusters C19MC and miR-371-3 does not play prominent role in thyroid cancer. Mol Cytogenet (2012) 0.77
MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET. Onco Targets Ther (2016) 0.75
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75
MicroRNA-520c enhances cell proliferation, migration, and invasion by suppressing IRF2 in gastric cancer. FEBS Open Bio (2016) 0.75
Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma. PLoS One (2016) 0.75
MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression. J Cancer Res Clin Oncol (2016) 0.75
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Prediction of mammalian microRNA targets. Cell (2003) 53.70
GenePattern 2.0. Nat Genet (2006) 29.07
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Hepatocellular carcinoma. Lancet (2003) 22.54
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics (2001) 16.47
Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet (2005) 15.96
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res (1982) 11.72
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
MicroRNAs as oncogenes and tumor suppressors. N Engl J Med (2005) 5.67
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res (2004) 4.19
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology (2010) 3.37
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol (2010) 3.27
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells (2008) 3.14
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Comprehensive microRNA profiling reveals a unique human embryonic stem cell signature dominated by a single seed sequence. Stem Cells (2008) 2.52
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One (2007) 2.32
Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One (2009) 2.21
Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol Reprod (2009) 2.17
Regulation of macropinocytosis by p21-activated kinase-1. Mol Biol Cell (2000) 2.16
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Mol Biol Evol (2008) 1.77
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
MicroRNA-based therapeutics for cancer. BioDrugs (2009) 1.45
Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics (2009) 1.29
FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology (2008) 1.20
The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS One (2010) 1.18
Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics (2007) 1.10
miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology (2010) 0.84
Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model. Hepatol Res (2000) 0.81
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatocellular carcinoma. Lancet (2012) 18.09
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62